Zymeworks Inc. 8-K

What Happened Zymeworks Inc. announced on April 1, 2026 (8-K filed) that Kristin Stafford, age 44, has been appointed Executive Vice President, Chief Financial Officer, effective April 1, 2026, and has assumed the roles of principal financial officer and principal accounting officer. Ms. Stafford joins from Royalty Pharma plc, where she served as Senior Vice President, Chief Accounting Officer, and is a CPA and current board member of NovoCure Limited. Kenneth Galbraith ceased serving as interim CFO as of the start date but remains Chair, CEO and President.

Key Details

• Base pay and bonus: $520,000 annual base salary; eligible for an annual discretionary bonus of up to 45% of base salary (including pro rata for 2026).
• Signing and equity: $52,000 signing bonus; stock options to purchase 178,000 shares (exercise price = fair market value at grant); 119,000 RSUs vesting 25% annually over 4 years; additional 50,000 RSUs vesting 1/3 annually over 3 years.
• Severance and benefits: If terminated without cause, 12 months’ base salary (increased with tenure up to 18 months after 4+ years), COBRA health/dental continuation; if terminated without cause within 12 months after a Change of Control, 18 months’ base salary, up to 18 months COBRA coverage, and full acceleration of equity.
• Other: Employment agreement filed as Exhibit 10.1 to the 8-K; standard indemnification agreement to be entered; no related-party arrangements or family relationships reported.

Why It Matters This filing signals a permanent CFO hire after an interim period, giving investors clarity on who will lead Zymeworks’ finance and reporting functions. Compensation and equity grants align Ms. Stafford’s pay with typical biotech CFO packages—base salary, performance bonus opportunity, and multi-year equity vesting—while severance and change-of-control protections could affect future cash obligations and equity dilution timing if triggered.